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Abstract
Purpose: The purpose of this study was to assess the efficacy of adding “Glycerineplus Honey” to standard management protocol, in terms of time to delay in oralmucositis ≥ grade 2. Methods: Hundred patients of oral cavity and oropharangealcancers, planned for concurrent chemoradiation (Dose: 60–66 Gy/30-33 fractions)were randomized 1:1 to receive either home-made remedy made of “Glycerine plusHoney” added to the standard management protocol to prevent mucositis versusstandard treatment alone. CTCAE v 4 (Common toxicity criteria for adverse events)was used for assessing oral mucositis scores weekly. Chi square test was used tocompare mucositis scores, weight loss, opioid use, ryles tube feeding, andunplanned treatment breaks in each cohort. Independent T-test was used tocompare means to assess the effect of treatment in delaying mucositis ≥ grade 2.
Results: Significantly higher number of patients developed grade ≥ 2 mucositis incontrol arm [n = 43 (86%)] compared to study arm [n = 30 (60%)] (p = 0.003).CTCAE scores favored Glycerine plus honey at week 4, and on last day ofradiotherapy. Whereas, time to first occurrence of oral mucositis grade ≥ 2 was23.17 (± 1.01) days for study arm [radiation dose 31.67 Gy (± 1.44)], it was 20.65(± 0.8) days for control arm [radiation dose 28.14 Gy (± 1.16)] (p = 0.05). Studypatients had lesser weight loss (2.76 kg) than control subjects (3.9 kg) with p =0.008. There were significantly higher number of patients in control arm whorequired opioid analgesia, ryles tube insertion and had unplanned treatmentbreaks, compared to study arm. Conclusion: Glycerine plus honey demonstratedsuperiority in delaying oral mucositis, and the combination is safe and welltolerable.
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1. IntroductionThe standard of care for head and neck cancersespecially oropharyngeal cancers and inoperable oralcavity cancers, is concurrent chemoradiation.1 Oralmucositis is the most common and irritating side effectof chemoradiation. At least 30-40% of the patients whotake chemotherapy drugs, experience some degrees ofmucositis which starts five to ten days after theinitiation of the treatment regimen.2 Not only does itadversely affects the quality of life, but also is associatedwith radiation treatment breaks and hospitalizations. Anumber of commercial agents have been marketed toprevent and treat oral mucositis, but these are expensiveand have doubtful efficacy.3 In developing countries likeours, where finances are the major issue, somehome-made remedy can help the poor patients to deal
with this chemoradiation induced side effect andcontinue their treatment without breaks. Glycerine andhoney are the two such natural, cheap and easilyavailable products. Glycerine has the hygroscopicproperty and honey is known for its natural healing andregenerative power,4-7 the properties which can helpcombat the treatment related mucositis. In thisrandomized trial, the study patients were asked to applythe paste made by mixture of these two products orally,starting from the day of radiation till treatmentcompletion, along with the standard managementalready being given in our institute, to prevent and treatoral mucositis. Whether this helps to delay the onset ofmucositis or not, as compared to those patients who are
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managed by standard protocols only, was analyzed inthe present study.
2. Methods and MaterialsIn this prospective double arm study, 100 patients wererandomized by Simple randomization method, wherepatients were recruited in 1:1 ratio into study andcontrol groups, based on even and odd numbers (Evennumber recruited into Study arm and Odd number intoControl arm). All locally advanced (Stage III and IV), nonmetastatic, inoperable, biopsy proven cases of squamouscell carcinoma of oral cavity and oropharynx, withKarnofsky Performance Status ≥ 80, fit for concurrentchemotherapy and those who were willing to giveinformed consent were included in the study. Thepostoperative cases of head and neck cancers, and thecancers of larynx, hypopharynx, nasopharynx wereexcluded from the trial.All the patients underwent standard clinical stagingwork up which included complete medical history andsystemic physical examination including the oral cavityexamination, full blood counts and biochemical profile,chest radiograph, biopsy from growth and contrastenhanced computed tomography of head and neckregion.
2.1. Treatment PlanningThe patients were treated by conventional radiotherapy,by two parallel opposed fields, for the dose of 60 – 66 Gydelivered in 30 – 33 fractions (spine shielding done after40 Gy), to the primary tumor and the drainage area.They were given concurrent chemotherapy withCisplatin (100 mg/m2) every three weeks, which is thestandard protocol followed in our institute to treat suchpatients.
2.2. InterventionThe study group was asked to apply the thick viscidpaste of glycerine plus honey in 1:1 ratio, post meals,with a target dosing frequency of three times per daybeginning on the first day of radiation and continuinguntil the last day of radiation therapy. Patients wereadvised to refrain from eating or drinking for one hourpost dosing. This was in addition to the standardtreatment offered to the patients receiving radiation inour institute, to prevent mucositis. The control groupwas advised to have the standard treatment only i.eplenty of fluids (2-3 litres per day), combined anestheticand antacid solution (containing Oxetacaine (10 mg),Aluminium hydroxide (291 mg),Magnesium (98 mg)] inthe syrup form and gargles with analgesic tablets(containing acetylsalicylic acid). Patients were providedsupportive therapy as needed including analgesics,antiemetics, antifungal therapy, hydration, or othertreatment. Agents suggested to modify oral mucositisrisk or course including amifostine, benzydamine,cevimeline, glutamine rinse, topical GM-CSF,
interleukin-11, chlorhexidine, hydrogen peroxide,diphenhydramine, paliferim, pilocarpine, steroid rinses,and various oral rinse medical devices were excluded.All patients were assessed weekly for oral mucositisscores using CTCAE v 4 (Common toxicity criteria foradverse events). Any treatment break, opiod use,emergency OPD visits or need for Ryles tube placementwas checked. Also, patients were assessed for anychange in weight at the end of the treatment.
2.3. Statistical AnalysisThe statistical analysis was conducted using SPSSversion 19. P value < 0.05 was considered statisticallysignificant. An Independent T test was used to comparethe means to assess the effect of treatment on the delayof mucositis ≥ grade 2. Chi square test was used tocompare the numbers of patients in each cohort incomparisons of oral mucositis scores, weight loss, opioiduse, frequency of ryles tube feeding, and unplannedbreaks in treatment.
3. Results
3.1. Patient characteristics (Table 1)100 patients were enrolled in the study and wereequally distributed among the two treatment arms.There was no difference between study and controlarms in terms of mean age, sex ratio and baselineweight. All the patients were locally advanced withmajority having primary tumor origin from oropharynx,with base of tongue as the most common subsite. Fromthe Table 1, it can be seen that number of patients of oralcavity tumors and oropharyngeal tumors, were notsignificantly different between the two arms. Therefore,the extent of oral mucosa irradiated though different intwo sets of patients (i.e in oral cavity and oropharyngealtumors) will not contribute to difference in number ofpatients with radiation mucositis among the two arms.In both the treatment arms, majority of the patientswere treated upto the dose of 60 Gy in 30 fractions over6 weeks with concurrent 3-weekly chemotherapy. The pvalue is not significant among the two arms, suggestingthat radiation dose and number of chemotherapy cyclesreceived by patients, contributed equally as a co factorfor radiation mucositis in both the arms.
3.2. Subjects with severe oral mucositis anytime
during radiotherapy (Table 2)Significantly higher number of patients developed Gd ≥ 2mucositis in the control arm (n = 43 (86%) compared tothe study arm (n = 30 (60%) (p = 0.003). However thedifference between number of patients who developedGd ≥ 3 mucositis anytime during radiotherapy could notreach statistical significance between the two arms (p =0.07).
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Table 1: Patient profileCharacteristic Study armN = 50 Control armN = 50 PAge (years)Mean (SD)Range 50.82 (9.7)28 - 68 49.36 (10.95)28 - 67 0.48SexMaleFemale 47 (94%)3 (6%) 47 (94%)3 (6%) 0.66Baseline weight (Kg)Mean (SD)Range 62.70 (11.90)32 – 89 61.98 (9.76)40 - 80 0.74Site of primary tumourOral cavityOropharynx 14 (28%)36 (72%) 18 (36%)32 (64%) 0.26Subsite of primary tumourOral cavityTongueFloor of mouthRetromolar trigoneHard palateBuccal mucosaOropharynxBase of tongueTonsilSoft palate
101112
3231
122-22
2192AJCC StageIIIIVaIVb 18 (36%)29 (58%)3 (6%) 25 (50%)22 (44%)3 (6%) 0.42Radiation dose planned60 Gy66 Gy 39 (78%)11 (22%) 42 (84%)8 (16%) 0.30Number of 3 - weeklychemotherapy cycles23 39 (78%)11 (22%) 42 (84%)8 (16%) 0.30
Table 2: Subjects with severe oral mucositis anytime during radiotherapy among treatment groupsCharacteristic Study arm Control arm paNumber of patients who developed Gd ≥ 2 mucositis anytimeduring radiotherapy 30 (60%) 43 (86%) 0.003Number of patients who developed Gd ≥ 3 mucositis anytimeduring radiotherapy 10 (20%) 18 (36%) 0.07aChi square test
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Table 3: Subjects with severe oral mucositis at Week 4, Day 1 and at the end of radiation therapy among treatment groups.Characteristic Study arm Control arm paSubjects with Gd ≥ 2 oral mucositis at week 4, day 1 20 (40%) 38 (76%) 0.001Subjects with Gd ≥ 3 oral mucositis at week 4, day 1 2 (4%) 9 (18%) 0.03Subjects with Gd ≥ 2 oral mucositis at end ofradiotherapy 28 (56%) 43 (86%) 0.002Subjects with Gd ≥ 3 oral mucositis at end ofradiotherapy 1 (2%) 4 (8%) 0.36aChi square test
3.3. Subjects with severe oral mucositis at mid
interval and at the end of radiotherapy among
treatment groups (Table 3)Assesssment of oral mucositis was performed at start ofradiation week 4 and on last day of radiotherapy. CTCAEscores trended in favor of Glycerine plus honey at week4, with mucositis (Gd ≥ 2) occurring in 20 (40%)patients only in study arm versus 38 (76%) in controlarm with p = 0.001. Also, severe mucositis (Gd ≥ 3)occurred in 2 (4%) patients only in study arm versus 9(18%) in the control arm, with p = 0.03. On the last dayof radiotherapy, statistically significant benefit (P =0.002) was seen in study arm for Gd ≥ 2 mucositis withfrequency of 28 (56%) patients in study arm developingGd ≥ 2 mucositis versus 43 (86%) patients in the controlarm. The trend noted for severe mucositis Gd ≥ 3 washowever not significantly different among the two arms(p = 0.36) on the last day of radiotherapy.
3.4. Delay in onset of Gd ≥ 2 mucositis among
the treatment groups (Table 4)Glycerine plus honey appeared to delay the onset ofsignificant oral mucositis Gd ≥ 2. Whereas, time to firstoccurrence of oral mucositis Gd ≥ 2 was 23.17 (± 1.01)
days (approximately 3 weeks and 2 days) for study arm,it was 20.65 (± 0.8) days (approximately 2 weeks and 6days) for control arm (p = 0.05). Similarly, the meancumulative radiation dose at which patients developedGd ≥ 2 mucositis was 31.67 Gy (± 1.44) among study armversus 28.14 Gy (± 1.16) among the control arm (p =0.06).
3.5. Change in body weight from baseline among
the treatment groups (Table 5)
3.6. Comparison of Opioid use, ryles tube
insertion, treatment breaks among the two
treatment groups (Table 6)There were significantly higher number of patients inthe control arm who required opioid analgesia duringtreatment, required ryles tube insertion and hadunplanned treatment breaks, compared to the studyarm. However, there were no relevant differences withrespect to number of days for which opioid analgesiawas required and number of days of treatment breakamong the two treatment arms. All patients who hadtreatment breaks were restarted on treatment after gapcorrection.Study patients had significantly lesser weight loss thancontrol subjects (2.76 Kg loss versus 3.9 Kg loss) with p =0.008.
Table 4: Delay in onset of Gd ≥ 2 mucositis in terms of time to first occurrence and dose of first occurrence of mucositisamong the two treatment groups.Characteristic Study arm Control arm paTime to First Occurrence of Gd ≥ 2 mucositis (in days)Mean (SE)Median (SD)Range 23.17 (1.01)22 (5.54)(15 – 36) 20.65 (0.8)22 (5.24)(15 – 36) 0.05Delay in Onset of Gd ≥ 2 mucositisin terms of radiotherapy dose (Gy)Mean (SE)Median (SD)Range
31.67 (1.44)30 (7.91)20 - 50 28.14 (1.16)30 (7.63)20 – 50 0.06
aIndependent T test
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Table 5: Change in body weight from baseline among the treatment groups.Characteristic Study arm Control arm paBaselineMean (SD)MedianRange 62.70 (11.90)60.5032 - 89 61.98 (9.76)6240 – 80 0.74At the end of treatmentMean (SD)MedianRange 58.88 (12.17)5830 - 87 57.98 (9.7)5835 – 78 0.39Change in weight from baseline to the end of treatmentMean (SD)MedianRange - 2.76- 2.000 -7 - 3.9- 4.02 - 11 0.008aChi square test
Table 6: Comparison of Opioid use, ryles tube insertion, treatment breaks among the two treatment groups.Characteristic Study arm Control arm paPatients who received opioid analgesiaNOpioid analgesia (no. of days required)Mean (SD)Range
15 (30%)10.27 (4.48)7 - 21
24 (48%)11.96 (6.46)5 – 21
0.070.13
Patients who required ryles tube insertionN 9 (18 %) 19 (38 %) 0.04Patients who had unplanned treatment breaksNNumber of days of treatment breakMean (SD)MedianRange
9 (18 %)8.67 (1.01)7 (3.04)7- 14
19 (38 %)7.37 (0.77)7 (3.37)3 – 14
0.040.33
4. DiscussionOral mucositis is one of the frequent complications ofcancer treatment, and is experienced in some degrees byalmost all head and neck cancer patients undergoingconcurrent chemoradiation.1, 3 Undoubtedly, its effectivetherapy can substantially reduce the oral complicationsand the risk of oral and systemic infections.Most of the medical devices available in market arecostly, have doubtful efficacy, and also use chemicalsthat may have ill effect on the health. In a country likeIndia, where finances are the major issue for majority ofpatients with head and neck cancer, some cheap, easilyavailable and indigenous home-made remedy can dealwith this chemoradiation induced side effect.Glycerine is a sweet and colourless liquid, and is onesuch natural and cheap product, which due to itshygroscopic property has the ability to attract moisturefrom the air and hold it. When diluted to a concentrationbelow 50%, it acts as a lubricant, emollient anddemulcent. Also, glycerine and water act together topromote softness and flexibility and prevent drying out
of mucosa.4 Study by Mouly et al. showed thatoxygenated glycerol triester lubricant oral spray wassuperior to saliva substitute Saliveze in improvingxerostomia and oral tissue condition in olderinstitutionalized patients.8Another natural product is honey which contains morethan 200 substances such as sugars, proteins, minerals,some vitamins, organic acids and antioxidants (phenoliccompounds, enzymes, flavonoids, amino acids,carotenoid-like substances and other phytochemicals).9Honey by its antioxidants, can increase cytokine releaseand has antimicrobial effects. It reduces inflammationand edema, stimulates epithelialisation and tissueregeneration and thus improves granulation anddebridement which in turn accelerates tissue repair andleads to wound healing. It is also known to stimulatesalivary secretion by its sweetness. Raeessi et al. in arandomized controlled trial showed that combination ofhoney and coffee significantly decreased the oralmucositis scores compared to topical steroids in thetreatment of chemoradiation induces oral mucosistis.5
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Previously also, some studies have proved promisingeffects of honey on the cancer treatment induced oralmucositis.6, 7Though, the above two products have been used eitheralone or in combination with some other products inliterature, this is probably the first study where the twohave been used in combination. Whether thiscombination helps to delay the onset of mucositis or not,as compared to those patients who are managed bystandard protocols alone, was analyzed in this trial.The study findings showed that there was a statisticallysignificant reduction in the degree of oral mucositis inthe course of radiotherapy with the use of honey andglycerine, compared to standard protocol. Overall, only60% patients (30) in study arm compared to 86% (43)in control arm developed Gd ≥ 2 mucositis (p = 0.003).However the difference between number of patientswho developed Gd ≥ 3 mucositis anytime duringradiotherapy could not reach statistical significancebetween the two arms (p = 0.07). The result is inaccordance with the study by Biswal et al.10 and Maiti et
al.,11 who evaluated the effect of honey in managementof radiation induced mucosits, in which only 18 - 20%patients in experimental group developed grade III orgrade IV mucositis compared to 41 - 75% patients incontrol group.On assessment of oral mucositis scores at start ofradiation week 4, it was found that CTCAE scorestrended in favor of Glycerine plus honey, with mucositis(Gd ≥ 2) occurring in 20 (40%) patients only in studyarm versus 38 (76%) in control arm with p = 0.001. Also,severe mucositis (Gd ≥ 3) occurred in 2 (4%) patientsonly in study arm versus 9 (18%) in the control arm,with p = 0.03. Compared to this, on the last day ofradiotherapy, total 28 (56%) patients in study arm hadGd ≥ 2 mucositis versus 43 (86%) patients in the controlarm. This indicates 16% increase in number of patientswho develop Gd ≥ 2 mucositis since week 4 till the lastday, compared to only 10% increase in number ofpatients in control arm. This odd increase in oralmucositis scores in study arm can be explained by thefact that, 19 patients (38%) had unplanned treatmentbreak in the control arm due to Gd ≥ 3 mucositis,compared to 9 patients only (19%) in the study arm.Thereby 38% patients in the control arm got adequatetime for their oral mucositis grades to heal and resolve.In addition, honey plus glycerine use was associatedwith other favorable outcomes compared to the control.Whereas the time to first occurrence of oral mucositisGd ≥ 2 was 20.65 (± 0.8) days (approximately 2 weeksand 6 days) in control arm, similar frequency of oralmucositis was not seen in study group until 23.17 (±1.01) days (approximately 3 weeks and 2 days). Also, themean cumulative radiation dose at which patientsdeveloped Gd ≥ 2 mucositis was 31.67 Gy (± 1.44)
among study arm versus 28.14 Gy (± 1.16) among thecontrol arm (p = 0.06). Similar results were shown byJayalekshmi et al in her study,12 who found that the timeto first occurrence of mucositis Gd ≥ 2 was 14 days ( 20Gy) in control group and 21 days (30 Gy) in study group(patients who had topical application of honey),however the results could not achieve statisticalsignificance in her study.Besides this, the study patients had significantly lesserweight loss than control subjects (2.76 Kg loss versus 3.9Kg loss) with p = 0.008. Biswal et al.10 in his study alsofound that the compliance of honey-treated group ofpatients was better than controls. 55% patients treatedwith topical honey showed no change or a positive gainin body weight compared to 25% in the control arm (p=0.053), the majority of whom lost weight.In our study, there were significantly higher number ofpatients in the control arm who required opioidanalgesia during treatment, required ryles tubeinsertion and had unplanned treatment breaks,compared to the study arm. However, the number ofdays for which opioid analgesia was required and thenumber of days of treatment break were not statisticallydifferent among the two treatment arms.A metaanalysis was conducted by Cho et al.13 on theeffects of honey on oral mucositis in patients with headand neck cancer. Nine studies comprising 476 patientswere included in this meta-analysis. It was found thatthe incidence of moderate to severe mucositis and themean mucositis grade during the first 3 weeks oftherapy were significantly lower in the honey groupthan the control group. Additionally, the onsetof mucositis was significantly later in the honey groupthan the control. Although there were no significantdifferences in the incidences of microbial colonizationand pain experienced between the two groups, theincidence of weight loss was significantly lower inthe honey group than control group.Compared to honey, the use of glycerol for preventingmucositis has rarely been found in literature. In one ofthe study conducted by Srivastava et al.14 in 69 patientsof head and neck cancer, 48 patients were treated withthe Orosol liquid solution (Filmogen glycerol containingprocyanidin fraction of plant tannins) and 21 withglycerol as a spray. A statistically significant differencein mucositis healing was observed in the Orosol groupcompared to the glycerol group. The study therebyconcluded that filmogen liquid glycerol applied as pasteattracts hypotonic liquid for a much longer period oftime, cleans the lesion, and helps promote recovery.Apart from the patient compliance to the use of thishomemade mixture, limited patient number was majorlimiting factor of this study. Further randomized trialswith larger number of patients can better approve the
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results of this study. And if approved, this can be a majorturnover in the prevention and treatment ofchemoradiation induced oral mucositis, as both glyceroland honey are cheap, easily available and indigenousremedies, free from any side effects. Besides this, Qualityof life (QOL) assessment was not taken up in this study,as the focus of this research was to find out the efficacyof “glycerine and honey” in delaying chemoradiationinduced mucositis. However, QOL assessment could alsohave contributed in demonstrating superiority of“glycerine and honey” in such patients, who areotherwise treated by standard protocols to preventchemoradiation induced mucositis.
5. ConclusionThis study represents the first report on thecombination of glycerol and honey for preventing anddelaying oral mucositis. The study results support theaddition of glycerol and honey to the standardmanagement protocol used for the management of oralmucositis in patients of head and neck cancers beingtreated with concurrent chemoradiation. The product ischeaper compared to currently practiced/recommendedagents for oral mucositis. Moreover, both the productsdid not produce any side effects and were well toleratedby most of the patients.
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